Tilray: A Global Leader

Gen3 Color Bar-01.png
 

Tilray is a global leader in medical cannabis research, cultivation, processing and distribution. We aspire to lead, legitimize and define the future of our industry by building the world’s most trusted cannabis company.

A proud pioneer, we are the first GMP-certified medical cannabis producer to supply cannabis flower and extract products to tens of thousands of patients, physicians, pharmacies, hospitals, governments and researchers on five continents.

 
b-07.png

EXPERIENCE

Tilray's experience is unmatched worldwide. Our team of 240+ professionals on the ground in 7 countries serves thousands of patients around the globe. Our 60,000-square foot flagship cultivation facility is among the most advanced in the world.

PRECISION

Tilray is the first GMP-certified medical cannabis producer to supply cannabis flower and extracts. All of our products are produced with meticulous care to ensure the highest quality, consistency and purity for our patients.

Lima01.jpg

RESEARCH

We are committed to scientific research that leads to an improved quality of life for patients in a time frame that matters. We partner with leading hospitals and universities to advance the clinical applications of cannabinoids.

x-06.png

CARE

Tilray takes tremendous pride in our customer service, patient outreach, and physician interaction. We recognize the importance of tracking potential adverse events as well as therapeutic benefits in order to ensure the safety of our patients.

Precisely formulated Products

Tilray cultivates a wide range of strains to meet patient needs including indicas, sativas, hybrids, and CBD-rich varieties. Medical cannabis is available in two primary forms: extracts and dried flower. Each can be administered or consumed via a variety of methods.

We take a scientific approach to product development. Our product line focuses on active ingredients and standardized, well-defined preparations. We use formulations and delivery formats that are intended to allow for consistent and measured dosing, and we test all of our products for potency and purity. Each of our commercial products are developed with comprehensive analysis and thorough documentation, including stability profiles, certificates of analysis, monographs and drug master files. 

Global Gen III Group Image.png
 

Advancing Cannabinoid Science

For the therapeutic value and risks of cannabinoid-based medicines to be fully understood, Tilray believes it is critical to evolve current scientific understanding of the field. Our clinical research program is designed with that in mind. 

Participation in clinical trials is a differentiating element of our research and development program. We have developed techniques that achieve clinical grade isolates in order to facilitate participation in clinical trials conducted by select research partners at world-leading hospitals and universities. 

Flagship Facility Tour: Tilray Nanaimo 

 

Production Process

Tilray choreographs a complex series of cutting-edge processes to deliver unparalleled product to its patients. From cultivation to shipping, Tilray's team brings precision, professionalism and care to each stage of the process.

process.png

Locations

As laws and regulations regarding medical cannabis evolve in different jurisdictions, we are actively seeking to expand our operations.

world map2-02.png
 

AUSTRALIA & NEW ZEALAND

Tilray currently serves patients in Australia and New Zealand on a compassionate access basis. In September 2016, Tilray became the first company to legally export medical cannabis products from North America to Australia for research and compassionate access purposes.
 

CANADA
 

In 2014, Tilray began operating in Canada. Today, Tilray is the country's leading scientifically rigorous provider of medical cannabis, supplying tens of thousands of patients in every province with consistent access to whole flower, milled blends and oils.

 

EUROPE


In June 2016, Tilray became the first company to legally export medical cannabis products from North America to Europe. In 2017, Tilray received a cultivation license from the Government of Portugal to produce products for the EU market. Tilray products are currently available at pharmacies in countries throughout the EU.

LATIN
AMERICA

In February 2017, Tilray announced a strategic agreement to distribute Tilray products in Chile and Brazil. Tilray products are currently available in Chilean pharmacies. The company also supplies patients in Argentina on a compassionate access basis. 

Management

Tilray's diverse management team of industry-leading experts includes PhD research scientists, master horticulturists, engineers, and patient advocates.

Board of Directors

Brendan Kennedy: Tilray CEO

Brendan Kennedy is CEO of Tilray, a global leader in medical cannabis research, production, and distribution. Brendan brings a strong background of entrepreneurship and hands-on business experience at the forefront of the venture backed-business community to Tilray. As a member of the founding team at SVB Analytics, a non-bank affiliate of Silicon Valley Bank, he managed an international team that rendered valuation opinions for emerging growth technology, life science and venture capital companies. He is also the co-founder of Privateer Holdings, the world's first private equity firm to invest exclusively in legal cannabis, which has raised $200+ million to build a global portfolio of leading cannabis businesses. He holds a B.A. from the University of California, Berkeley; an M.S. from the University of Washington; and an M.B.A. from the Yale School of Management

Christine St.Clare: Ret. Partner, KPMG

Christine St.Clare founded St.Clare Advisors, LLC in September 2010 and currently serves as its President. Prior to founding her own firm, Christine was a partner at KPMG LLP, where she was an Audit Partner from 1986 to 2005 and Advisory Partner from 2006 to 2010. During her time at KPMG, Christine served as Lead Audit Partner for some of the firm’s largest retail clients and served a four-year term on KPMG’s Board of Directors. She currently is an Independent Director of Fibrocell Science, Inc., and AquaBounty Technologies, Inc. and was an Independent Director for AVINTIV, Inc.  (formerly known as Polymer Group, Inc.) prior to the sale of the company.

Rebekah Dopp: Principal, Google

Rebekah Dopp is Principal, News and Local Media – Global Partnerships at Google. She joined the company in September 2016 as Head of Local TV Partnerships for YouTube TV. Prior to joining Google, Rebekah was Senior Vice President, Advanced Services for CBS Corporation (CBS). She began her media career at Home Box Office, Inc. (HBO) where she spent 14 years in leadership positions in technology and distribution, culminating in her role as Vice President, Global Technology Business Management. Rebekah has led global teams negotiating complex agreements with domestic and international technology partners and affiliates and was on the launch teams for streaming TV services HBO GO, CBS All Access, and YouTube TV.

Scotty Greenwood: Principal, Dentons

Maryscott “Scotty” Greenwood currently serves as CEO of the Canadian American Business Council and as Principal at Dentons U.S. LLP (Dentons) in the firm’s Public Policy Group and as co-leader of the practice’s Advocacy and Government Affairs team. Immediately before joining Dentons in 2001, Scotty spent four years as chief of staff of the U.S. Embassy in Canada as a Presidential appointee. From 1993 to 1997, Scotty was director of intergovernmental affairs for the City of Atlanta, handling state and federal relations, including working on several projects related to the 1996 Centennial Olympic Games.

Michael Auerbach: Senior Vice President, Albright Stonebridge Group

Michael Auerbach currently serves as Senior Vice President at Albright Stonebridge Group (ASG) and General Partner at Subversive Capital.  Prior to joining ASG, he served as a Vice President at global risk consultancy Control Risks. A dot-com bubble veteran, Michael started his career in technology, running Panopticon Inc., a VC incubator concentrating on internet and mobile technology. Michael has held senior positions at the Center for American Progress and The Century Foundation, where he concentrated on issues related to U.S. Foreign Policy, National Security, and Conflict Resolution. 

Medical Advisory Board

Orrin Devinsky, MD, Chairman

Orrin Devinsky, MD, Chairman, is Director of the Comprehensive Epilepsy Center at the NYU Langone Medical Center. His research interests include the use of cannabinoids and other medications to treat a variety of epilepsy syndromes. He has served on the Board of Directors of the American Epilepsy Society, the Epilepsy Foundation and the Epilepsy Therapy Project, as well as the Scientific Advisory Boards of numerous disease organization. Dr. Devinsky has been an invited speaker at international epilepsy and neurology conferences for more than 20 years, and has authored over 400 peer-reviewed scientific articles and 20 books and monographs.

Praveen Anand, MD

Praveen Anand, MD, is Head of the Centre for Clinical Translation and Professor of Clinical Neurology at Imperial College London. His research focuses on pathophysiological and molecular mechanisms in human sensory neuropathies and chronic pain syndromes. As Head of the Centre for Clinical Translation, he oversees the research and development of novel therapies for neurological diseases. Dr. Anand has worked extensively with pharmaceutical companies enabling translational research that has guided the recent success of three novel drugs from the laboratory to Phase II trials. He has published over 200 peer-reviewed articles in journals including Nature, Nature Medicine, Nature Genetics, Science and The Lancet.

Abraham Chachoua, MD

Abraham Chachoua, MD, is Associate Director of Cancer Services at the NYU Langone Perlmutter Cancer Center and the Jay and Isabel Fine Professor of Oncology at the NYU Langone Department of Medicine. He specializes in the treatment of cancers that affect the lungs and chest. He has been involved in a number of clinical trials for the treatment of non-small cell lung cancer. Dr. Chachoua has a particular interest in the study of novel targeted therapies and earlier intervention in disease, integrating multiple modalities for the treatment of locally advanced lung cancer.

Elizabeth K. Hale, MD

Elizabeth K. Hale, MD, is a Clinical Associate Professor of Dermatology at NYU Langone Medical Center and the co-Founder of CompleteSkinMD in New York City. She specializes in laser surgery and cosmetic dermatology. Dr. Hale has extensive experience in the field of skin cancer and is a senior vice president of the Skin Cancer Foundation. She has been named a “Best Doctor in Dermatology” by New York Magazine and a “Super Doctor” by the New York Times for the past five years. Dr. Hale has been an invited lecturer at international conferences focused on skin cancer and its treatment. Dr. Hale has authored over 40 peer-reviewed articles and more than 10 textbooks and chapters.

Catherine Lord, PhD

Catherine Lord, PhD, is Professor of Psychology in Psychiatry and founding Director of the Center for Autism and the Developing Brain (CADB), a collaborative program between New York-Presbyterian Hospital, Weill Cornell Medicine, and Columbia University College of Physicians and Surgeons in partnership with New York Collaborates for Autism. She is internationally recognized for her work in longitudinal studies of children with autism as well as for her role in developing the autism diagnostic instruments used in both practice and in research worldwide today.

 

Tilray Updates

 

Tilray in the Press

Videos